Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study

Nicolò Bizzarri, Valentina Ghirardi, Valentino Remorgida, Pier Luigi Venturini, Simone Ferrero

Research output: Contribution to journalArticlepeer-review

Abstract

Abstract Objective To compare the usefulness of preoperative treatment with triptorelin, letrozole or ulipristal acetate or no treatment before hysteroscopic removal of uterine submucosal myomas. Study design Single center prospective non-randomized comparative pilot study. The study included consecutive premenopausal patients undergoing hysteroscopic resection of myomas graded as type 0, type 1 or type 2 according to the FIGO classification with diameter between 20 and 35 mm. Exclusion criteria were: associated polyps, associated non-hysteroscopic surgical procedures, >2 myomas requiring hysteroscopic resection. This study enrolled patients who underwent either direct surgery (group S; n = 23) or 3-month preoperative treatment with triptorelin (3.75 mg every 28 days; group T; n = 20), letrozole (2.5 mg/day; group L; n = 11) or ulipristal acetate (5 mg/day; group U; n = 7). Patients underwent hysteroscopic resection of the myomas. Results All medical treatments caused a significant decrease in the volume of myomas (group T, p

Original languageEnglish
Article number9027
Pages (from-to)22-26
Number of pages5
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume192
DOIs
Publication statusPublished - Sep 1 2015

Keywords

  • GnRH analog therapy
  • Hysteroscopy
  • Letrozole
  • Myomectomy
  • Submucous fibroid
  • Triptorelin

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Fingerprint Dive into the research topics of 'Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study'. Together they form a unique fingerprint.

Cite this